Regeneron Pharmaceuticals Inc
REGN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of REGN by members of U.S. Congress
REGN Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
REGN Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
REGN Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by REGN's directors and management
Government lobbying spending instances
-
$400,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$400,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$430,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$400,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jul 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$320,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$340,000 Jul 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Apr 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues
-
$370,000 Jan 20, 2022 Issue: None
-
$360,000 Oct 20, 2021 Issue: None
-
$310,000 Jul 20, 2021 Issue: None
-
$330,000 Apr 20, 2021 Issue: None
-
$330,000 Jan 21, 2021 Issue: None
-
$480,000 Oct 20, 2020 Issue: None
-
$320,000 Jul 20, 2020 Issue: None
-
$370,000 Apr 20, 2020 Issue: None
-
$340,000 Jan 21, 2020 Issue: None
-
$180,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Copyright/Patent/Trademark
-
$250,000 Jul 22, 2019 Issue: Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues Medicare/Medicaid
-
$300,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$180,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$190,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$200,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$260,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$120,000 Oct 20, 2017 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$120,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Budget/Appropriations
-
$240,000 Apr 20, 2017 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
-
$130,000 Jan 20, 2017 Issue: Health Issues Medicare/Medicaid
-
$130,000 Oct 20, 2016 Issue: Health Issues
-
$120,000 Jul 20, 2016 Issue: Health Issues
-
$50,000 Apr 19, 2016 Issue: Health Issues
-
$50,000 Jan 16, 2016 Issue: Health Issues
-
$50,000 Oct 20, 2015 Issue: Health Issues
-
$50,000 Jul 20, 2015 Issue: Health Issues
-
$60,000 Apr 20, 2015 Issue: Health Issues
-
$52,000 Jan 19, 2015 Issue: Health Issues
-
$50,000 Oct 20, 2014 Issue: Health Issues
-
$50,000 Jul 21, 2014 Issue: Health Issues
-
$50,000 Jan 22, 2014 Issue: Health Issues
-
$50,000 Oct 21, 2013 Issue: Health Issues
-
$40,000 Jul 22, 2013 Issue: Health Issues
-
$30,000 Apr 24, 2013 Issue: Health Issues
-
$30,000 Feb 02, 2013 Issue: Health Issues
-
$30,000 Oct 31, 2012 Issue: Health Issues
Estimated quarterly lobbying spending
REGN Revenue by Segment or Geography
By Segment
By Geography
REGN Income Statement
REGN Balance Sheet
REGN Cash Flow
U.S. Patents
New patents grants
-
Patent Title: Humanized m-csf mice Oct. 29, 2024
-
Patent Title: Heavy peptide approach to accurately measure unprocessed c-terminal lysine Oct. 22, 2024
-
Patent Title: Methods of treating liver diseases with phosphodiesterase 3b (pde3b) inhibitors Oct. 22, 2024
-
Patent Title: Packaging Oct. 22, 2024
-
Patent Title: Identification of host cell proteins Oct. 15, 2024
-
Patent Title: Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf Oct. 15, 2024
-
Patent Title: Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof Oct. 15, 2024
-
Patent Title: Models of tauopathy Oct. 08, 2024
-
Patent Title: Vegf traps and mini-traps and methods for treating ocular disorders and cancer Oct. 01, 2024
-
Patent Title: Use of liquid chromatography and mass spectrometry to characterize oligonucleotides Sep. 24, 2024
-
Patent Title: Non-human animals having a humanized lymphocyte-activation gene 3 Sep. 24, 2024
-
Patent Title: Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation Sep. 17, 2024
-
Patent Title: Anti-pfrh5 antibodies and antigen-binding fragments thereof Sep. 17, 2024
-
Patent Title: Il2 and peptide-mhc complex fusion proteins and methods of use thereof Sep. 17, 2024
-
Patent Title: Methods for treating atopic dermatitis by administering an il-4r antagonist antibody Sep. 17, 2024
-
Patent Title: Glucagon-like peptide 1 receptor agonists and uses thereof Sep. 17, 2024
-
Patent Title: Nucleic acids comprising a modified rodent activin a receptor type 1 (acvr1) gene Sep. 17, 2024
-
Patent Title: Genetically modified mouse that expresses humanized pd1 and pd-l1 proteins Sep. 17, 2024
-
Patent Title: Packaging Sep. 17, 2024
-
Patent Title: Anti-c5 antibody combinations and uses thereof Sep. 10, 2024
-
Patent Title: Treatment of hyperglycemia with solute carrier family 39 member 5 (slc39a5) inhibitors Sep. 10, 2024
-
Patent Title: Rodent animals expressing human cr1 Sep. 10, 2024
-
Patent Title: Non-human animals models of retinoschisis Sep. 10, 2024
-
Patent Title: Viral clearance by low ph hold Sep. 03, 2024
-
Patent Title: Multispecific antigen-binding molecules for cell targeting and uses thereof Sep. 03, 2024
-
Patent Title: Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies Sep. 03, 2024
-
Patent Title: Anti-cd8 antibodies and uses thereof Sep. 03, 2024
-
Patent Title: Anti-vegf protein compositions and methods for producing the same Sep. 03, 2024
-
Patent Title: Methods and systems for detection of abnormal karyotypes Aug. 27, 2024
-
Patent Title: Steroids and antibody-conjugates thereof Aug. 27, 2024
-
Patent Title: Process for reducing subvisible particles in a pharmaceutical formulation Aug. 27, 2024
-
Patent Title: Methods of treating skin cancer with carboxypeptidase vitellogenic like (cpvl) inhibitors Aug. 27, 2024
-
Patent Title: Anti-factor xii/xiia antibodies and uses thereof Aug. 20, 2024
-
Patent Title: Target residual moisture content for lyophilized drug product Aug. 20, 2024
-
Patent Title: Genetic modification of rats Aug. 20, 2024
-
Patent Title: Multispecific antigen-binding molecules for cell targeting and uses thereof Aug. 20, 2024
-
Patent Title: Anti-tmprss2 antibodies and antigen-binding fragments Aug. 20, 2024
-
Patent Title: Humanized t cell co-receptor mice Aug. 20, 2024
-
Patent Title: Support for test device Aug. 20, 2024
-
Patent Title: Methods and compositions for modifying a targeted locus Aug. 13, 2024
-
Patent Title: Anti-il36r antibodies Aug. 13, 2024
-
Patent Title: Cd79a chimeric antigen receptors Aug. 13, 2024
-
Patent Title: Mouse having a humanized b-cell activating factor gene Aug. 13, 2024
-
Patent Title: Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay Aug. 06, 2024
-
Patent Title: Liquid chromatography-mass spectrometry (lc-ms) methods for analyzing ampholyte lot variation Aug. 06, 2024
-
Patent Title: Fucosylation-deficient cells Aug. 06, 2024
-
Patent Title: Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer Aug. 06, 2024
-
Patent Title: Anti-vegf protein compositions and methods for producing the same Aug. 06, 2024
-
Patent Title: Anti-vegf protein compositions and methods for producing the same Aug. 06, 2024
-
Patent Title: Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging Aug. 06, 2024
Government Contracts
Federal grants, loans, and purchases
- $494,095 2021-11-24 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-09-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $148,229 2021-09-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-04-07 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $2,625,000,000 2021-01-12 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
Government Contracts
Estimated quarterly amount awarded from public contracts
REGN News
Recent insights relating to REGN
CNBC Recommendations
Recent picks made for REGN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in REGN
REGN Analyst Ratings
REGN Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
REGN Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $REGN stock a Buy, Sell, or Hold?
- What is the price target for $REGN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
REGN Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $REGN stock?
- Who owns the most shares of $REGN stock?
- What funds own $REGN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
REGN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view REGN Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More